**Supplementary Table S2.** Clinicopathologic and molecular features

of immunotherapeutic patients in MSKCC and GLCI cohorts.

|  |  |  |
| --- | --- | --- |
|  | **MSKCC cohort** | **GLCI cohort** |
| **No. of**  **patients** | 34 | 20 |
| **Age** |  |  |
| **Mean, yrs** | 62.0 | 57.0 |
| **Range** | 41 – 80 | 50 – 75 |
| **Gender** | |  |
| **Male** | 16 (47.1) | 17 (45.7) |
| **Female** | 18 (52.9) | 3 (54.3) |
| **Smoking** |  |  |
| **Never** | 6 (17.6) | 5 (7.5) |
| **Ever** | 28 (82.4) | 15 (75.8) |
| **Histology** |  |  |
| **ADC** | 29 (85.3) | 15 (60.0) |
| **Non-ADC** | 5 (14.7) | 5 (15.6) |
| **PD-L1** |  |  |
| **Strong** | 10 (29.4) | 4 (20.0) |
| **Weak** | 14 (41.2) | 3 (15.0) |
| **Negative** | 6 (17.6) | 6 (30.0) |
| **Unknown** | 4 (11.8) | 7 (35.0) |
| **EGFR** | |  |
| **Mutation** | 2 (11.9) | 2 (10.0) |
| **Wild type** | 32 (88.1) | 18 (90.0) |
| **KRAS** | |  |
| **Mutation** | 8 (23.8) | 3 (15.0) |
| **Wild type** | 26 (77.2) | 17 (85.0) |
| **TP53** | |  |
| **Mutation** | 15 (52.8) | 8 (40.0) |
| **Wild type** | 19 (47.2) | 8 (40.0) |
| **Unknown** | 0 | 4 (20.0) |
| Abbreviations: MSKCC, Memorial Sloan Kettering Cancer Center; GLCI, Guangdong Lung Cancer Institute; ADC, adenocarcinoma; PD-L1, Programmed death-ligand 1; EGFR, epidermal growth factor receptor. | | |